Study Summary
This study aims to evaluate the safety, efficacy and duration of response of CD19 Chimeric Antigen Receptor (CAR) redirected autologous T-cells in patients with high risk, relapsed CD19+ haematological malignancies.
Interested in this trial?
Submit an InquiryInterventions
Anti-CD19-CARBIOLOGICAL
Cells extracted, followed by induction chemotherapy before CD19-CAR infusion (dose escalation.)
Study Locations
No locations listed.